Survey of antimicrobial resistance in clinical Burkholderia pseudomallei isolates over two decades in Northeast Thailand.

Abstract

A 21-year survey conducted in northeast Thailand of antimicrobial resistance to parenteral antimicrobial drugs used to treat melioidosis identified 24/4,021 (0.6%) patients with one or more isolates resistant to ceftazidime (n = 8), amoxicillin-clavulanic acid (n = 4), or both drugs (n = 12). Two cases were identified at admission, and the remainder were detected a median of 15 days after starting antimicrobial therapy. Resistance to carbapenem drugs was not detected. These findings support the current prescribing recommendations for melioidosis.

• Authors: Vanaporn Wuthiekanun, Premjit Amornchai, Natnaree Saiprom, Narisara Chantratita, Wirongrong Chierakul, Gavin C K W Koh, Wipada Chaowagul, Nicholas P J Day, Direk Limmathurotsakul, Sharon J Peacock
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 55 Issue 11 Pg. 5388-91 (Nov 2011) ISSN: 1098-6596 [Electronic] United States
• PMID: 21876049 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-Bacterial Agents
• Thienamycins
• Imipenem
• Amoxicillin-Potassium Clavulanate Combination
• Ceftazidime
• Meropenem

Topics

• Amoxicillin-Potassium Clavulanate Combination (therapeutic use)
• Anti-Bacterial Agents (therapeutic use)
• Burkholderia pseudomallei (drug effects, pathogenicity)
• Ceftazidime (therapeutic use)
• Drug Resistance, Bacterial
• Humans
• Imipenem (therapeutic use)
• Melioidosis (drug therapy)
• Meropenem
• Thailand
• Thienamycins (therapeutic use)